Synaptogenix 8/14/2024 Earnings Report

Synaptogenix EPS Results

• Actual EPS: -$1.18
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Synaptogenix Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Synaptogenix Announcement Details

• Date: 8/14/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Synaptogenix (NASDAQ:SNPX) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of small‐molecule therapeutics aimed at preserving or restoring synaptic function in neurodegenerative diseases. Its research focuses on addressing the cognitive impairment associated with conditions such as Alzheimer’s disease by targeting pathways critical to neuronal communication and synaptic health.

The company’s lead candidate is in early‐phase clinical studies to assess safety, tolerability and potential efficacy in improving cognitive deficits. Leveraging a proprietary drug discovery platform, Synaptogenix has built a pipeline of novel compounds designed to modulate key synaptic processes and slow disease progression. Research collaborations with academic institutions and neuroscience centers support its preclinical and clinical development efforts.

Based in the United States, Synaptogenix operates laboratories and research facilities focused exclusively on neuroscience drug discovery. The management team brings together professionals with extensive experience in biotechnology and neurodegenerative disease research, guiding the company’s mission to develop innovative treatments for patients suffering from cognitive disorders.